PRF Technologies (PRFX) Accumulated Expenses (2019 - 2025)
PRF Technologies (PRFX) posted quarterly Accumulated Expenses of $1.9 million for Q4 2025, down 1.89% year-on-year from $1.9 million in Q4 2024, and up 2.02% on a QoQ basis from $1.8 million in Q2 2025.
PRF Technologies (PRFX) Accumulated Expenses (2019 - 2025) Analysis & Trends
PRF Technologies (PRFX) has reported Accumulated Expenses for 7 consecutive years, with $1.9 million the latest figure, recorded in Q4 2025.
- Quarterly Accumulated Expenses fell 1.89% year-over-year to $1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 million (down 1.89% YoY) and the FY2025 annual result came in at $1.9 million, down 1.89% from the prior year.
- Accumulated Expenses advanced to $1.9 million in Q4 2025 per PRFX's latest filing, from $1.8 million in the prior quarter.
- Over the last five years, Accumulated Expenses for PRFX reached as high as $4.3 million in Q2 2024 and fell as low as $53000.0 in Q2 2022.
- A 5-year average of $998294.1 and a median of $499000.0 in 2022 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses plunged 90.47% — and 2024, when it soared 1513.56%.
- Year by year, Accumulated Expenses stood at $423000.0 in 2021, then gained by 17.97% to $499000.0 in 2022, then tumbled by 76.35% to $118000.0 in 2023, then surged by 1513.56% to $1.9 million in 2024, then slipped by 1.89% to $1.9 million in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $1.9 million, $1.8 million, and $1.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.87 Mn |
| Jun 30, 2025 | 1.83 Mn |
| Dec 31, 2024 | 1.90 Mn |
| Jun 30, 2024 | 4.28 Mn |
| Mar 31, 2024 | 2.47 Mn |
| Dec 31, 2023 | 118,000.00 |
| Sep 30, 2023 | 460,000.00 |
| Jun 30, 2023 | 525,000.00 |
| Mar 31, 2023 | 437,000.00 |
| Dec 31, 2022 | 499,000.00 |
| Sep 30, 2022 | 395,000.00 |
| Jun 30, 2022 | 53,000.00 |
| Mar 31, 2022 | 121,000.00 |
| Dec 31, 2021 | 423,000.00 |
| Sep 30, 2021 | 457,000.00 |
| Jun 30, 2021 | 556,000.00 |
| Mar 31, 2021 | 582,000.00 |
| Dec 31, 2020 | 149,000.00 |
| Dec 31, 2019 | 151,000.00 |